focus -WSS

focus

author：Wikipedia 2025-09-29 13:30:50 - browse：793

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： How the Dana

Wikipedia

WSS

Boston competes with Raleigh

Biogen walks away from Aduhelm, years after polarizing approval

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Health Care Service Corp to buy Cigna Medicare Advantage plans

hotspot

focus

explore

How one medical school became remarkably diverse

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Intercept Pharmaceuticals sells itself for less than $1 billion

ChatGPT in medicine: STAT answers readers' burning questions

Address the ethical violations that led to 'Three Identical Strangers'

Hollywood unions extend contract negotiations for actors

Pancreatic cancer early detection could be helped by AI

The high cost of giving birth even with insurance

Bernie Sanders is gearing up to subpoena pharma CEOs

focus

After a drawn out lobbying fight, ARPA

Biogen walks away from Aduhelm, years after polarizing approval

How the Dana

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Pancreatic cancer early detection could be helped by AI

Health Care Service Corp to buy Cigna Medicare Advantage plans

Wikipedia

leisure time

focus

hotspot